Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Felder

Pediatrics Hattiesburg, MS Medical Doctor

NPI 1134174097 CMS profile 936459

102 Medical Park, Hattiesburg, MS 39401

Open in the dashboard

General payments

$4,352

249 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Felder of Hattiesburg, MS is reported in the CMS Open Payments database as having received $4,352 across 249 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $666 42
2024 General $1,436 66
2023 General $690 49
2022 General $678 39
2021 General $231 12
2020 General $127 7
2019 General $525 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Felder
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Elizabeth Felder were reported at $666. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Elizabeth Felder Pediatrics median Middle half National median
2019 $525 $86 $31–$183 $163
2020 $127 $49 $22–$110 $114
2021 $231 $68 $27–$158 $132
2022 $678 $77 $30–$173 $149
2023 $690 $88 $33–$190 $160
2024 $1,436 $94 $34–$206 $164
2025 $666 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tris Pharma Inc $1,472 89 payments
  2. Supernus Pharmaceuticals, Inc. $932 23 payments
  3. Corium, Inc. $751 55 payments
  4. Ironshore Pharmaceuticals Inc. $650 42 payments
  5. Shire North American Group Inc $155 14 payments
  6. Noven Therapeutics, LLC $146 10 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $86 6 payments
  8. Collegium Pharmaceutical, Inc. $81 5 payments
  9. Neos Therapeutics, LP $60 4 payments
  10. Arbor Pharmaceuticals, Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,352 249 payments
Products named General payments · program years 2019–2025
  1. Dyanavel XR Adhd $935 56 payments
  2. Azstarys $751 55 payments
  3. Qelbree Viloxazine Hydrochloride $672 13 payments
  4. Dyanavel XR Adhd $416 24 payments
  5. JORNAY PM Central Nervous System Stimulant $384 31 payments
  6. QELBREE Psychology $261 10 payments
  7. VYVANSE $241 20 payments
  8. Jornay PM 20mg capsules (Bottle of 100) $151 5 payments
  9. Xelstrym $146 10 payments
  10. JORNAY PM Central Nervous Stimulant ADHD $114 6 payments
  11. Other $341 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

249 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record